New Cancer Antigens Found in Liver Cancer Patients
Author Information
Author(s): Dong X-Y, Su Y-R, Qian X-P, Yang X-A, Pang X-W, Wu H-Y, Chen W-F
Primary Institution: Peking University Health Science Center
Hypothesis
Can novel cancer-testis (CT) antigens elicit an immune response in hepatocellular carcinoma patients?
Conclusion
The study identified two novel CT antigens, FATE/BJ-HCC-2 and TPTE/BJ-HCC-5, which are immunogenic in hepatocellular carcinoma patients.
Supporting Evidence
- FATE/BJ-HCC-2 was expressed in 66% of hepatocellular carcinoma samples.
- TPTE/BJ-HCC-5 was expressed in 39% of hepatocellular carcinoma samples.
- Antibodies against FATE/BJ-HCC-2 were found in 4.8% of patients.
- Antibodies against TPTE/BJ-HCC-5 were found in 9.6% of patients.
Takeaway
Researchers found two new proteins that can help the body's immune system fight liver cancer.
Methodology
The study involved analyzing human tumor tissues and sera, using RT-PCR and ELISA to assess the expression of the identified antigens.
Limitations
The study's findings are based on a limited number of patients and may not be generalizable.
Participant Demographics
Patients were HBV surface antigen positive and HCV antigen negative.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website